OM:SUS

Stock Analysis Report

Surgical Science Sweden

Executive Summary

Surgical Science Sweden AB (publ) develops and markets virtual reality (VR) simulators for evidence based laparoscopic and endoscopic training.


Snowflake Analysis

Flawless balance sheet with high growth potential.

Share Price & News

How has Surgical Science Sweden's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: SUS's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

9.2%

SUS

3.0%

SE Medical Equipment

4.0%

SE Market


1 Year Return

98.5%

SUS

15.8%

SE Medical Equipment

-6.4%

SE Market

Return vs Industry: SUS exceeded the Swedish Medical Equipment industry which returned 12.7% over the past year.

Return vs Market: SUS exceeded the Swedish Market which returned -13.2% over the past year.


Shareholder returns

SUSIndustryMarket
7 Day9.2%3.0%4.0%
30 Day-3.2%0.2%-8.3%
90 Day-39.3%-9.2%-17.8%
1 Year98.5%98.5%17.7%15.8%-4.4%-6.4%
3 Yearn/a37.7%22.0%6.8%-8.3%
5 Yearn/a25.7%3.7%13.7%-9.9%

Price Volatility Vs. Market

How volatile is Surgical Science Sweden's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Surgical Science Sweden undervalued compared to its fair value and its price relative to the market?

49.0%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: SUS (SEK253) is trading below our estimate of fair value (SEK518.26)

Significantly Below Fair Value: SUS is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: SUS is poor value based on its PE Ratio (113.2x) compared to the Medical Equipment industry average (49.7x).

PE vs Market: SUS is poor value based on its PE Ratio (113.2x) compared to the Swedish market (14.6x).


Price to Earnings Growth Ratio

PEG Ratio: SUS is poor value based on its PEG Ratio (1.7x)


Price to Book Ratio

PB vs Industry: SUS is overvalued based on its PB Ratio (4.2x) compared to the SE Medical Equipment industry average (3.7x).


Next Steps

Future Growth

How is Surgical Science Sweden forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

64.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SUS's forecast earnings growth (64.7% per year) is above the savings rate (-0.4%).

Earnings vs Market: SUS's earnings (64.7% per year) are forecast to grow faster than the Swedish market (8.3% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: SUS's revenue (36.1% per year) is forecast to grow faster than the Swedish market (4.1% per year).

High Growth Revenue: SUS's revenue (36.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: SUS's Return on Equity is forecast to be low in 3 years time (19%).


Next Steps

Past Performance

How has Surgical Science Sweden performed over the past 5 years?

6.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SUS has high quality earnings.

Growing Profit Margin: SUS became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: SUS has become profitable over the past 5 years, growing earnings by 6.1% per year.

Accelerating Growth: SUS has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: SUS has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (12.6%).


Return on Equity

High ROE: SUS's Return on Equity (3.1%) is considered low.


Next Steps

Financial Health

How is Surgical Science Sweden's financial position?


Financial Position Analysis

Short Term Liabilities: SUS's short term assets (SEK112.8M) exceed its short term liabilities (SEK39.6M).

Long Term Liabilities: SUS's short term assets (SEK112.8M) exceed its long term liabilities (SEK15.0M).


Debt to Equity History and Analysis

Debt Level: SUS is debt free.

Reducing Debt: SUS has no debt compared to 5 years ago when its debt to equity ratio was 7.8%.

Debt Coverage: SUS has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: SUS has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is Surgical Science Sweden's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate SUS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate SUS's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SUS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SUS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SUS's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.4yrs

Average management tenure


CEO

Gisli Hennermark (47yo)

5.25s

Tenure

Mr. Gisli Hennermark serves as Chief Executive Officer of Surgical Science Sweden AB (publ) since 2015. He received MSc from Stockholm School of Economics and Cornell University. He worked previously as a  ...


Leadership Team

NamePositionTenureCompensationOwnership
Gisli Hennermark
Chief Executive Officer5.25yrsno data1.05% SEK19.8m
Anna Ahlberg
Chief Financial Officer2.25yrsno datano data
Anders Larsson
Co-Founder & CTO0.25yrno data0.31% SEK5.9m
Anders Melander
Director of Global Sales5.25yrsno datano data
Hans Uddenberg
Market Director0.25yrno datano data
Tommy Forsell
Director of Global Sales Industry & OEM and Director1.25yrsno datano data
Daniel Evestedt
Head of Development0.42yrno datano data

0.4yrs

Average Tenure

47yo

Average Age

Experienced Management: SUS's management team is not considered experienced ( 0.4 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Tommy Forsell
Director of Global Sales Industry & OEM and Director1.25yrsno datano data
Roland Bengtsson
Chairman of the Board3.25yrsno data18.67% SEK351.6m
Jan Bengtsson
Director15.25yrsno datano data
Thomas Eklund
Director3.25yrsno data0.0073% SEK136.5k
Nils Sellbom
Director8.25yrsno data0.065% SEK1.2m

3.3yrs

Average Tenure

64yo

Average Age

Experienced Board: SUS's board of directors are considered experienced (3.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 15.9%.


Top Shareholders

Company Information

Surgical Science Sweden AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Surgical Science Sweden AB (publ)
  • Ticker: SUS
  • Exchange: OM
  • Founded: 1999
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: kr1.883b
  • Shares outstanding: 6.90m
  • Website: https://www.surgicalscience.com

Location

  • Surgical Science Sweden AB (publ)
  • Drakegatan 7 A, 3 tr.
  • Gothenburg
  • Västra Götaland County
  • 412 50
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SUSOM (OMX Nordic Exchange Stockholm)YesShare CapitalSESEKJun 2017
4P4DB (Deutsche Boerse AG)YesShare CapitalDESEKJun 2017

Biography

Surgical Science Sweden AB (publ) develops and markets virtual reality (VR) simulators for evidence based laparoscopic and endoscopic training. It offers LapSim training system comprising LapSim essence, a portable and ready-to-use VR simulator that fills the gap between lo-fi simulators and fully loaded VR systems; LapSim Haptic System, a force feedback technology with the graphics and cognitive instruction that allows navigation on two touch screens; and LapSim Basic Skills module, which offers a portfolio of laparoscopic exercises that range from basic navigation to advanced suturing. The company also provides EndoSim system, an endoscopy simulator that delivers medical simulation training; TeamSim, a dynamic platform for inter-professional education development taking surgery simulation into the real world teamwork; and Simball Box, which offers feedback on velocity with tutorial task videos showing a preferred approach. Surgical Science AB was founded in 1999 and is headquartered in Gothenburg, Sweden. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/08 01:37
End of Day Share Price2020/04/07 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.